Cameron Turtle - Feb 1, 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Executive Officer, Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
SYRE
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/2/2024, 08:31 PM
Previous filing
Nov 27, 2023
Next filing
Feb 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +278K $0.00 278K Feb 1, 2024 Common Stock 278K $25.86 Direct F1

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 277,750 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.